Ionis

D., chief executive officer at Ionis, and a founding scientist at Ionis who led the discovery and development of TEGSEDI.

Allianz Asset Management GmbH lessened its stake in Ionis Pharmaceuticals, Inc. () by 99.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC.

Captrust Financial Advisors lifted its position in Ionis Pharmaceuticals by 21.1% in the second quarter.

Creative Planning increased its holdings in shares of Ionis Pharmaceuticals by 9.1% in the 3rd quarter.

Finally, First Trust Advisors LP boosted its holdings in Ionis Pharmaceuticals by 30.1% during the third quarter.

Finally, Seven Eight Capital LP lifted its holdings in shares of Ionis Pharmaceuticals by 13.2% during the 4th quarter.

In January, Ionis announced it had sold an interest in two of its medicines to Royalty Pharma for $500 million upfront and up to $625 million in additional payments based on future production.

PNC Financial Services Group Inc. grew its holdings in Ionis Pharmaceuticals by 9.4% during the 1st quarter.

Vanguard Group Inc. grew its holdings in shares of Ionis Pharmaceuticals by 5.0% during the third quarter.

Wipfli Financial Advisors LLC acquired a new position in shares of Ionis Pharmaceuticals during the 3rd quarter worth approximately $27,000.

Almanack Investment Partners LLC. purchased a new stake in Ionis Pharmaceuticals in the third quarter worth $44,000.

Finally, Horizon Investments LLC increased its position in Ionis Pharmaceuticals by 29.6% in the second quarter.

Quantbot Technologies LP purchased a new stake in Ionis Pharmaceuticals in the 2nd quarter valued at $44,000.

This table compares Aytu Bioscience and Ionis Pharmaceuticals’ net margins, return on equity and return on assets.

William Blair reaffirmed a hold rating on shares of Ionis Pharmaceuticals in a research report on Wednesday, August 5th.

Advisory Services Network LLC lifted its holdings in shares of Ionis Pharmaceuticals by 38.5% in the second quarter.

Also, Chairman Stanley T. Crooke sold 46,904 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Wednesday, February 13th.

Cantor Fitzgerald began coverage on Ionis Pharmaceuticals in a report on Tuesday, April 9th.

DNB Asset Management AS lifted its position in Ionis Pharmaceuticals by 5.3% in the third quarter.

Finally, Zacks Investment Research lowered Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, April 5th.